A Double-blind, Placebo-controlled, Randomized Study Examining the Effects of Nebivolol Compared to Atenolol on Endothelial Function and Cardiovascular Risk in Patients With Early Vascular Disease

Trial Profile

A Double-blind, Placebo-controlled, Randomized Study Examining the Effects of Nebivolol Compared to Atenolol on Endothelial Function and Cardiovascular Risk in Patients With Early Vascular Disease

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Nov 2017

At a glance

  • Drugs Nebivolol (Primary) ; Atenolol
  • Indications Hypertension; Vascular disorders
  • Focus Pharmacodynamics
  • Acronyms EVIDENCE
  • Most Recent Events

    • 28 Nov 2017 Results published in the Journal of Human Hypertension
    • 23 Dec 2016 Status changed from active, no longer recruiting to completed according to results presented at the 89th Annual Scientific Sessions of the American Heart Association..
    • 16 Nov 2016 Primary endpoint of endothelial function (change in small artery elasticity) has been met, according to results presented at the 89th Annual Scientific Sessions of the American Heart Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top